Nicotinic acetylcholine receptors (nAchRs) are not only key receptors in the autonomic nervous system, but also are present on immune cells. The alpha seven subunit of nAchR (a7nAchR) suppresses proinflammation in peripheral monocytes by decreasing pro-inflammatory cytokine production. In spinal cord, a7nAchRs are found on microglia, which are known to induce and maintain pain. We predicted that a7nAchR agonists might attenuate intrathecal HIV-1 gp120-induced, pro-inflammatory cytokine-and microglia-dependent mechanical allodynia. Choline, a precursor for acetylcholine and selective agonist for a7nAchR, was administered intrathecally either with, or 30 min after, intrathecal gp120. Choline significantly blocked and reversed gp120-induced mechanical allodynia for at least 4 h after drug administration. In addition, intrathecal choline, delivered either with or 30 min after gp120, reduced gp120-induced IL-1b protein and pro-inflammatory cytokine mRNAs within the lumbar spinal cord. A second a7nAchR agonist, GTS-21, also significantly reversed gp120-induced mechanical allodynia and lumbar spinal cord levels of pro-inflammatory cytokine mRNAs and IL-1b protein. A role of microglia is suggested by the observation that intrathecal choline suppressed the gp120-induced expression of, cd11b, a macrophage/microglial activation marker. Taken together, the data support that a7nAchR may be a novel target for treating pain where microglia maintain the pro-inflammatory state within the spinal cord.
Introduction
Nicotinic acetylcholine receptors (nAchRs) are ligand-gated ion channels with 16 known subunits (a1-7, 9 and 10, b1-4, d, e and c) (Conejero-Goldberg et al., 2008) . Nicotinic receptors are stimulated by acetylcholine and nicotine and are key receptors in neuromuscular junctions and in the peripheral and central nervous systems (Wang et al., 2003) . In addition to neural tissue, nAchR are found on peripheral monocytes, in particular the a7nAchR, which when activated suppress the release of the pro-inflammatory cytokines, tumor necrosis factor alpha (TNFa), interleukin-1b (IL-1b) (RosasBallina et al., 2009 ) and interleukin-6 (IL-6) (Waldburger et al., 2008) , at least in part via an inhibition of NFjB (Borovikova et al., 2000a (Borovikova et al., , 2000b Yoshikawa et al., 2006) . A growing body of literature documents that activation of a7nAchR on peripheral immune cells suppresses peripheral inflammation, a phenomenon integral to what has come to be referred to as the cholinergic antiinflammatory pathway (Borovikova et al., 2000b ).
The present series of studies explores the potential relevance of a7nAchR in pain control. Activation of glial cells (microglia and astrocytes) and the consequent release of glial pro-inflammatory cytokines are now recognized as being fundamentally important in the induction and maintenance of pathological pain states in animal models (Fields, 2009; Watkins et al., 2007) . As pathological pain in humans remain largely unresolved by currently available therapeutics, novel targets for pain control need to be explored. The clinical potential of targeting activated glia and their proinflammatory products is becoming increasingly recognized but is still in its infancy regarding the identification of optimal drug targets for controlling glially dependent pain. Intriguingly, while microglia, the resident macrophages of the central nervous system are known to express a7nAchR (Shytle et al., 2004) , the potential of a7nAchR agonists for controlling glially dependent pain has not previously been explored. Given the known anti-inflammatory effects of a7nAchR agonists on peripheral macrophages noted above, 
